- Home
- SKM vs ROIV Comparison
SKM vs ROIV Comparison
Compare SKM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKM
- ROIV
- Stock Information
- Founded
- SKM 1984
- ROIV 2014
- Country
- SKM South Korea
- ROIV United Kingdom
- Employees
- SKM N/A
- ROIV N/A
- Industry
- SKM Telecommunications Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SKM Telecommunications
- ROIV Health Care
- Exchange
- SKM Nasdaq
- ROIV Nasdaq
- Market Cap
- SKM 8.7B
- ROIV 8.4B
- IPO Year
- SKM 1996
- ROIV N/A
- Fundamental
- Price
- SKM $21.19
- ROIV $10.94
- Analyst Decision
- SKM Sell
- ROIV Strong Buy
- Analyst Count
- SKM 1
- ROIV 8
- Target Price
- SKM N/A
- ROIV $17.93
- AVG Volume (30 Days)
- SKM 220.2K
- ROIV 5.3M
- Earning Date
- SKM 11-06-2024
- ROIV 02-11-2025
- Dividend Yield
- SKM 3.19%
- ROIV N/A
- EPS Growth
- SKM 2.10
- ROIV N/A
- EPS
- SKM 3.97
- ROIV 5.89
- Revenue
- SKM $13,671,573,974.00
- ROIV $129,128,999.00
- Revenue This Year
- SKM $3.08
- ROIV $15.98
- Revenue Next Year
- SKM $1.71
- ROIV N/A
- P/E Ratio
- SKM $9.49
- ROIV $1.86
- Revenue Growth
- SKM 2.75
- ROIV 145.68
- 52 Week Low
- SKM $19.88
- ROIV $9.69
- 52 Week High
- SKM $24.58
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SKM 41.91
- ROIV 38.75
- Support Level
- SKM $20.85
- ROIV $10.42
- Resistance Level
- SKM $21.50
- ROIV $11.82
- Average True Range (ATR)
- SKM 0.26
- ROIV 0.35
- MACD
- SKM 0.03
- ROIV -0.11
- Stochastic Oscillator
- SKM 34.69
- ROIV 29.21
About SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 31 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 6.9 million broadband customers and 9.5 million pay TV customers (6.8 million IPTV and 2.7 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.